參考文獻 |
1. Galiniak, S., et al., “The possibilities of stem cell application in regenerative medicine”. Polish Hyperbaric Research, 2016. 54 (1): p. 49.
2. Samsonraj, R.M., et al., “Concise Review: Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine”. STEM CELLS Translational Medicine, 2017. 6 (12): p. 2173.
3. Biehl, J.K. and B. Russell, “Introduction to stem cell therapy”. The Journal of cardiovascular nursing, 2009. 24 (2): p. 98.
4. Marks, P. and S. Gottlieb, “Balancing safety and innovation for cell-based regenerative medicine”. New England Journal of Medicine, 2018. 378 (10): p. 954.
5. Mahla, R.S., “Stem Cells Applications in Regenerative Medicine and Disease Therapeutics”. International Journal of Cell Biology, 2016. 2016: p. 6940283.
6. Karussis, D., et al., “Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis”. Archives of neurology, 2010. 67 (10): p. 1187.
7. Yubo, M., et al., “Clinical efficacy and safety of mesenchymal stem cell transplantation for osteoarthritis treatment: a meta-analysis”. PloS one, 2017. 12 (4).
8. Lee, H.C., et al., “Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia”. Circulation Journal, 2012: p. 1204091686.
9. Kawamura, M., et al., “Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model”. Circulation, 2012. 126 (11_suppl_1): p. S29.
10. Zietlow, R., et al., “Human stem cells for CNS repair”. Cell and tissue research, 2008. 331 (1): p. 301.
11. Yi, S., et al., “Extracellular matrix scaffolds for tissue engineering and regenerative medicine”. Current stem cell research & therapy, 2017. 12 (3): p. 233.
12. Masumoto, H., et al., “Human iPS cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration”. Scientific reports, 2014. 4: p. 6716.
13. Patel, N.G. and G. Zhang, “Responsive systems for cell sheet detachment”. Organogenesis, 2013. 9 (2): p. 93.
14. Choi, A., et al., “Bulk poly (N-isopropylacrylamide)(PNIPAAm) thermoresponsive cell culture platform: toward a new horizon in cell sheet engineering”. Biomaterials science, 2019. 7 (6): p. 2277.
15. Sung, T.-C., et al., “Efficient differentiation of human pluripotent stem cells into cardiomyocytes on cell sorting thermoresponsive surface”. Biomaterials, 2020: p. 120060.
16. Matsuura, K., et al., “Cell sheet transplantation for heart tissue repair”. Journal of controlled release, 2013. 169 (3): p. 336.
17. Lane, S.W., et al., “Modulating the stem cell niche for tissue regeneration”. Nature biotechnology, 2014. 32 (8): p. 795.
18. Frese, L., et al., “Adipose tissue-derived stem cells in regenerative medicine”. Transfusion Medicine and Hemotherapy, 2016. 43 (4): p. 268.
19. Squillaro, T., et al., “Clinical trials with mesenchymal stem cells: an update”. Cell transplantation, 2016. 25 (5): p. 829.
20. Bindu A, H. and S. B, “Potency of Various Types of Stem Cells and their Transplantation”. Journal of Stem Cell Research & Therapy, 2011. 01 (03).
21. Kaebisch, C., et al., “The role of purinergic receptors in stem cell differentiation”. Computational and structural biotechnology journal, 2015. 13: p. 75.
22. Takahashi, K., et al., “Induction of pluripotent stem cells from adult human fibroblasts by defined factors”. Cell, 2007. 131 (5): p. 861.
23. Hu, B.-Y., et al., “Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency”. Proceedings of the National Academy of Sciences, 2010. 107 (9): p. 4335.
24. Lian, X., et al., “Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling”. Proceedings of the National Academy of Sciences, 2012. 109 (27): p. E1848.
25. Thomas, R.J., et al., “Automated, scalable culture of human embryonic stem cells in feeder‐free conditions”. Biotechnology and Bioengineering, 2009. 102 (6): p. 1636.
26. Braam, S.R., et al., “Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery”. Trends in pharmacological sciences, 2009. 30 (10): p. 536.
27. Nostro, M.C. and G. Keller. Generation of beta cells from human pluripotent stem cells: potential for regenerative medicine. in Seminars in cell & developmental biology. 2012. Elsevier.
28. Tabar, V. and L. Studer, “Pluripotent stem cells in regenerative medicine: challenges and recent progress”. Nature Reviews Genetics, 2014. 15 (2): p. 82.
29. Thomson, J.A., et al., “Embryonic stem cell lines derived from human blastocysts”. science, 1998. 282 (5391): p. 1145.
30. Pera, M.F., et al., “Human embryonic stem cells”. J Cell Sci, 2000. 113 (1): p. 5.
31. Stojkovic, M., et al., “Derivation of human embryonic stem cells from day‐8 blastocysts recovered after three‐step in vitro culture”. Stem Cells, 2004. 22 (5): p. 790.
32. Mitalipova, M., et al., “Human embryonic stem cell lines derived from discarded embryos”. Stem Cells, 2003. 21 (5): p. 521.
33. Vazin, T. and W.J. Freed, “Human embryonic stem cells: derivation, culture, and differentiation: a review”. Restorative Neurology and Neuroscience, 2010. 28 (4): p. 589.
34. Landry, D.W. and H.A. Zucker, “Embryonic death and the creation of human embryonic stem cells”. The Journal of clinical investigation, 2004. 114 (9): p. 1184.
35. Robertson, J.A., “Human embryonic stem cell research: ethical and legal issues”. Nature Reviews Genetics, 2001. 2 (1): p. 74.
36. Wert, G.d. and C. Mummery, “Human embryonic stem cells: research, ethics and policy”. Human reproduction, 2003. 18 (4): p. 672.
37. Okita, K., et al., “Generation of germline-competent induced pluripotent stem cells”. Nature, 2007. 448 (7151): p. 313.
38. Takahashi, K. and S. Yamanaka, “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors”. Cell, 2006. 126 (4): p. 663.
39. Yu, J., et al., “Induced pluripotent stem cell lines derived from human somatic cells”. science, 2007. 318 (5858): p. 1917.
40. Stadtfeld, M., et al., “Induced pluripotent stem cells generated without viral integration”. science, 2008. 322 (5903): p. 945.
41. Okita, K., et al., “Generation of mouse induced pluripotent stem cells without viral vectors”. science, 2008. 322 (5903): p. 949.
42. Okita, K., et al., “A more efficient method to generate integration-free human iPS cells”. Nature methods, 2011. 8 (5): p. 409.
43. Kaji, K., et al., “Virus-free induction of pluripotency and subsequent excision of reprogramming factors”. Nature, 2009. 458 (7239): p. 771.
44. Woltjen, K., et al., “piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells”. Nature, 2009. 458 (7239): p. 766.
45. Yusa, K., et al., “Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon”. Nature methods, 2009. 6 (5): p. 363.
46. Warren, L., et al., “Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA”. Cell Stem Cell, 2010. 7 (5): p. 618.
47. Lin, S.-L., et al., “Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state”. Rna, 2008. 14 (10): p. 2115.
48. Kim, D., et al., “Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins”. Cell Stem Cell, 2009. 4 (6): p. 472.
49. Zhou, H., et al., “Generation of induced pluripotent stem cells using recombinant proteins”. Cell Stem Cell, 2009. 4 (5): p. 381.
50. Kim, Y., et al., “Small molecule-mediated reprogramming of human hepatocytes into bipotent progenitor cells”. Journal of hepatology, 2019. 70 (1): p. 97.
51. Fusaki, N., et al., “Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome”. Proceedings of the Japan Academy, Series B, 2009. 85 (8): p. 348.
52. Seki, T., et al., “Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells”. Cell Stem Cell, 2010. 7 (1): p. 11.
53. Huang, C.Y., et al., “Human iPSC banking: barriers and opportunities”. Journal of Biomedical Science, 2019. 26 (1): p. 87.
54. Levy, D., et al., “Oxysterols and mesenchymal stem cell biology”. Chemistry and physics of lipids, 2017. 207: p. 223.
55. Dominici, M., et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement”. Cytotherapy, 2006. 8 (4): p. 315.
56. Caplan, A.I., “Mesenchymal stem cells”. Journal of orthopaedic research, 1991. 9 (5): p. 641.
57. Volarevic, V., et al., “Ethical and safety issues of stem cell-based therapy”. International journal of medical sciences, 2018. 15 (1): p. 36.
58. Yi, T. and S.U. Song, “Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications”. Archives of pharmacal research, 2012. 35 (2): p. 213.
59. Mazini, L., et al., “Regenerative capacity of adipose derived stem cells (ADSCs), comparison with mesenchymal stem cells (MSCs)”. International journal of molecular sciences, 2019. 20 (10): p. 2523.
60. Han, Y., et al., “Mesenchymal stem cells for regenerative medicine”. Cells, 2019. 8 (8): p. 886.
61. Martinelli, D., et al., “A humanized system to expand in vitro amniotic fluid-derived stem cells intended for clinical application”. Cytotherapy, 2016. 18 (3): p. 438.
62. Bertolo, A., et al., “An in vitro expansion score for tissue‐engineering applications with human bone marrow‐derived mesenchymal stem cells”. Journal of tissue engineering and regenerative medicine, 2016. 10 (2): p. 149.
63. De Coppi, P., et al., “Isolation of amniotic stem cell lines with potential for therapy”. Nature biotechnology, 2007. 25 (1): p. 100.
64. Borlongan, C.V., “Amniotic fluid as a source of engraftable stem cells”. Brain circulation, 2017. 3 (3): p. 175.
65. Ramasamy, T.S., et al., “Stem cells derived from amniotic fluid: a potential pluripotent-like cell source for cellular therapy?”. Current stem cell research & therapy, 2018. 13 (4): p. 252.
66. Loukogeorgakis, S.P. and P. De Coppi, “Concise review: amniotic fluid stem cells: the known, the unknown, and potential regenerative medicine applications”. Stem Cells, 2017. 35 (7): p. 1663.
67. Spitzhorn, L.-S., et al., “Isolation and molecular characterization of amniotic fluid-derived mesenchymal stem cells obtained from caesarean sections”. Stem cells international, 2017. 2017.
68. Magatti, M., et al., “The immunomodulatory properties of amniotic cells: The two sides of the coin”. Cell transplantation, 2018. 27 (1): p. 31.
69. Schiavo, A.A., et al., “Endothelial properties of third-trimester amniotic fluid stem cells cultured in hypoxia”. Stem cell research & therapy, 2015. 6 (1): p. 209.
70. Moschidou, D., et al., “Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach”. Molecular Therapy, 2012. 20 (10): p. 1953.
71. Moschidou, D., et al., “Human mid-trimester amniotic fluid stem cells cultured under embryonic stem cell conditions with valproic acid acquire pluripotent characteristics”. Stem cells and development, 2013. 22 (3): p. 444.
72. Su, C.-F., et al., “Application of amniotic fluid stem cells in repairing sciatic nerve injury in minipigs”. Brain research, 2018. 1678: p. 397.
73. Kumar, V., et al., Robbins and Cotran pathologic basis of disease, professional edition e-book. 2014: elsevier health sciences.
74. Hay, E.D., Cell biology of extracellular matrix. 2013: Springer Science & Business Media.
75. Higuchi, A., et al., “Biomimetic cell culture proteins as extracellular matrices for stem cell differentiation”. Chemical reviews, 2012. 112 (8): p. 4507.
76. Chen, K.G., et al., “Human pluripotent stem cell culture: considerations for maintenance, expansion, and therapeutics”. Cell Stem Cell, 2014. 14 (1): p. 13.
77. Plopper, G., et al., The extracellular matrix and cell adhesion, Cells. 2007, Jones and Bartlett, Sudbury.
78. Higuchi, A., et al., “Stem cell therapies for reversing vision loss”. Trends in biotechnology, 2017. 35 (11): p. 1102.
79. Higuchi, A., et al., “Polymeric design of cell culture materials that guide the differentiation of human pluripotent stem cells”. Progress in Polymer Science, 2017. 65: p. 83.
80. Higuchi, A., et al., “Physical cues of biomaterials guide stem cell differentiation fate”. Chemical reviews, 2013. 113 (5): p. 3297.
81. Wood, K.J., et al., “Understanding stem cell immunogenicity in therapeutic applications”. Trends in immunology, 2016. 37 (1): p. 5.
82. Moon, S.-H., et al., “A system for treating ischemic disease using human embryonic stem cell-derived endothelial cells without direct incorporation”. Biomaterials, 2011. 32 (27): p. 6445.
83. Drukker, M., et al., “Characterization of the expression of MHC proteins in human embryonic stem cells”. Proceedings of the National Academy of Sciences, 2002. 99 (15): p. 9864.
84. Li, L., et al., “Human embryonic stem cells possess immune‐privileged properties”. Stem Cells, 2004. 22 (4): p. 448.
85. Higuchi, A., et al., “Physical cues of cell culture materials lead the direction of differentiation lineages of pluripotent stem cells”. Journal of Materials Chemistry B, 2015. 3 (41): p. 8032.
86. Taylor, C.J., et al., “Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching”. The Lancet, 2005. 366 (9502): p. 2019.
87. Nakajima, F., et al., “Human leukocyte antigen matching estimations in a hypothetical bank of human embryonic stem cell lines in the Japanese population for use in cell transplantation therapy”. Stem Cells, 2007. 25 (4): p. 983.
88. Xu, H., et al., “Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility”. Cell Stem Cell, 2019. 24 (4): p. 566.
89. Han, X., et al., “Generation of hypoimmunogenic human pluripotent stem cells”. Proceedings of the National Academy of Sciences, 2019. 116 (21): p. 10441.
90. Higuchi, A., et al., “Differentiation ability of amniotic fluid-derived stem cells cultured on extracellular matrix-immobilized surface”. Current Nanoscience, 2011. 7 (6): p. 893.
91. Sung, T.-C., et al., “Effect of cell culture biomaterials for completely xeno-free generation of human induced pluripotent stem cells”. Biomaterials, 2020. 230: p. 119638.
92. Chen, Y.-M., et al., “Xeno-free culture of human pluripotent stem cells on oligopeptide-grafted hydrogels with various molecular designs”. Scientific reports, 2017. 7: p. 45146.
93. Higuchi, A., et al., “Long-term xeno-free culture of human pluripotent stem cells on hydrogels with optimal elasticity”. Scientific reports, 2015. 5: p. 18136.
94. Sung, T.-C., et al., “The design of a thermoresponsive surface for the continuous culture of human pluripotent stem cells”. Biomaterials, 2019. 221: p. 119411.
95. Kumar, S.S., et al., “The combined influence of substrate elasticity and surface-grafted molecules on the ex vivo expansion of hematopoietic stem and progenitor cells”. Biomaterials, 2013. 34 (31): p. 7632.
96. Higuchi, A., et al., “Direct ex vivo expansion of hematopoietic stem cells from umbilical cord blood on membranes”. Journal of Membrane Science, 2010. 351 (1-2): p. 104.
97. Moreau, J.L. and H.H. Xu, “Mesenchymal stem cell proliferation and differentiation on an injectable calcium phosphate–chitosan composite scaffold”. Biomaterials, 2009. 30 (14): p. 2675.
98. Bhattacharya, S., et al., “High efficiency differentiation of human pluripotent stem cells to cardiomyocytes and characterization by flow cytometry”. JoVE (Journal of Visualized Experiments), 2014 (91): p. e52010.
99. Shevde, N.K. and A.A. Mael, Techniques in embryoid body formation from human pluripotent stem cells, in Basic Cell Culture Protocols. 2013, Springer. p. 535.
100. Kurosawa, H., “Methods for inducing embryoid body formation: in vitro differentiation system of embryonic stem cells”. Journal of bioscience and bioengineering, 2007. 103 (5): p. 389.
101. Zhang, W.Y., et al., Teratoma formation: A tool for monitoring pluripotency in stem cell research, in StemBook [Internet]. 2012, Harvard Stem Cell Institute.
102. Führmann, T., et al., “Injectable hydrogel promotes early survival of induced pluripotent stem cell-derived oligodendrocytes and attenuates longterm teratoma formation in a spinal cord injury model”. Biomaterials, 2016. 83: p. 23.
103. Gholizadeh-Ghalehaziz, S., et al., “A mini overview of isolation, characterization and application of amniotic fluid stem cells”. International journal of stem cells, 2015. 8 (2): p. 115.
104. Davydova, D., et al., “Cell phenotypes in human amniotic fluid”. Acta Naturae (англоязычная версия), 2009. 1 (2 (2)).
105. Roubelakis, M.G., et al., “Amniotic fluid and amniotic membrane stem cells: marker discovery”. Stem cells international, 2012. 2012.
106. Li, L., et al., “Characteristics of human amniotic fluid mesenchymal stem cells and their tropism to human ovarian cancer”. PloS one, 2015. 10 (4).
107. Mummery, C.L., et al., “Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview”. Circulation research, 2012. 111 (3): p. 344.
108. Yamanaka, S., “Strategies and new developments in the generation of patient-specific pluripotent stem cells”. Cell Stem Cell, 2007. 1 (1): p. 39.
109. Moreau, A., et al., “Induced pluripotent stem-cell-derived cardiomyocytes: Cardiac applications, opportunities, and challenges”. Canadian journal of physiology and pharmacology, 2017. 95 (10): p. 1108.
110. Di Baldassarre, A., et al., “Human-induced pluripotent stem cell technology and cardiomyocyte generation: progress and clinical applications”. Cells, 2018. 7 (6): p. 48.
111. Wesselschmidt, R.L., The teratoma assay: an in vivo assessment of pluripotency, in Human Pluripotent Stem Cells. 2011, Springer. p. 231. |